Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group.

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
2.
3.

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

Russo EB.

Neurology. 2003 Feb 25;60(4):729-30; author reply 729-30. No abstract available.

PMID:
12601130
4.

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH.

Neurology. 2002 May 14;58(9):1404-7.

PMID:
12011290
5.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Rog DJ, Nurmikko TJ, Friede T, Young CA.

Neurology. 2005 Sep 27;65(6):812-9.

PMID:
16186518
7.
8.

Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.

Di Marzo V, Centonze D.

CNS Neurosci Ther. 2015 Mar;21(3):215-21. doi: 10.1111/cns.12358. Epub 2014 Dec 4. Review.

PMID:
25475413
9.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J.

Clin Rehabil. 2003 Feb;17(1):21-9.

PMID:
12617376
10.

Sativex for the management of multiple sclerosis symptoms.

Perras C.

Issues Emerg Health Technol. 2005 Sep;(72):1-4.

PMID:
16317825
11.
12.

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group.

Lancet. 2003 Nov 8;362(9395):1517-26.

PMID:
14615106
14.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
15.

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S.

J Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4. Epub 2012 Nov 21.

PMID:
23180178
16.

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O'Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z.

Neurol Res. 2010 Jun;32(5):451-9. doi: 10.1179/016164109X12590518685660. Epub 2010 Mar 19.

PMID:
20307378
17.

Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?

Metz L, Page S.

Lancet. 2003 Nov 8;362(9395):1513. No abstract available.

PMID:
14615102
18.

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.

Serpell MG, Notcutt W, Collin C.

J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z. Epub 2012 Aug 10.

PMID:
22878432
19.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Gras A, Broughton J.

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):771-779. Epub 2016 Feb 26.

PMID:
26750641
20.

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; Sativex Spasticity Study Group.

Eur J Neurol. 2011 Sep;18(9):1122-31. doi: 10.1111/j.1468-1331.2010.03328.x. Epub 2011 Mar 1.

PMID:
21362108

Supplemental Content

Support Center